外用马来酸噻吗洛尔凝胶治疗婴幼儿血管瘤中国专家共识

doi:10.19438/j.cjoms.2026.03.002

中国口腔颌面外科杂志 ›› 2026, Vol. 24 ›› Issue (3): 211-217.doi: 10.19438/j.cjoms.2026.03.002

外用马来酸噻吗洛尔凝胶治疗婴幼儿血管瘤中国专家共识

郑家伟^1*, 王绪凯^2*, 刘学键^3#, 江成鸿⁴, 秦中平⁵, 范新东⁶, 李凯⁷, 杨耀武⁸, 霍然⁹, 刘少华¹⁰, 赵吉宏¹¹, 汪小勇¹², 周德凯¹³, 雷少榕¹⁴, 吉毅¹⁵, 申刚¹⁶, 李海波¹⁷, 胡梵^18*, 吴海威¹⁹, 董长宪²⁰, 王杞章²¹, 王怀杰²², 郭晓楠²³, 高杨²⁴, 高西波²⁵, 郭磊^26#

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科,上海 200011;
2.中国医科大学口腔医学院口腔颌面外科, 辽宁沈阳 110001;
3.山东省第一康复医院两腺与血管瘤外科, 山东临沂 276034;
4.福建医科大学附属协和医院整形外科,福建福州 350001;
5.山东省临沂市肿瘤医院省 A级血管瘤特色专科,山东临沂 276001;
6.上海交通大学医学院附属第九人民医院介入科,上海 200011;
7.复旦大学附属儿科医院外科,上海 201102;
8.空军军医大学口腔医学院头颈肿瘤外科,陕西西安 710032;
9.山东省立医院烧伤整形美容外科,山东济南 250021;
10.山东大学齐鲁医院口腔颌面外科,山东济南 250012;
11.武汉大学口腔医学院口腔外科,湖北武汉 430079;
12.上海曹安医院血管瘤科,上海 201804;
13.重庆医科大学附属儿童医院胃肠新生儿外科血管瘤专科,重庆 400015;
14.中南大学湘雅医院整形美容外科,湖南长沙 410028;
15.四川大学华西医院小儿外科,四川成都 610041;
16.首都医科大学附属首都儿童医学中心·首都儿科研究所附属儿童医院介入血管瘤科,北京 100020;
17.广州市妇女儿童医疗中心介入&血管瘤科,广东广州 510623;
18.四川大学华西第二医院儿童心血管科, 四川成都 610041;
19.山东第一医科大学附属省立医院口腔颌面外科,山东济南 250021;
20.河南省人民医院血管瘤与脉管畸形科,河南郑州 450003;
21.四川大学华西口腔医院口腔外科,四川成都 610041;
22.西安国际医学中心医院小儿外科&血管瘤科,陕西西安 710100;
23.郑州大学第一附属医院血管瘤与脉管畸形外科, 河南郑州 450052;
24.河北省儿童医院血管瘤科（介入科）,河北石家庄 050031;
25.天津市儿童医院皮肤科,天津 300202;
26.山东大学附属儿童医院（济南市儿童医院）血管瘤与介入血管外科,山东济南 250022

收稿日期:2026-04-16 修回日期:2026-05-10 出版日期:2026-05-20 发布日期:2026-06-04
通讯作者: 郭磊,E-mail: etjrxgl@hotmail.com;刘学键, E-mail: Liuxj168@sina.com。^#共同通信作者
作者简介:郑家伟（1964—）,男,博士,教授,博士研究生导师,E-mail: davidzhengjw@hotmail.com;王绪凯（1955—）,男,博士,教授,博士研究生导师,E-mail: wangxukai757892@sina.com;胡梵（1981—）, 博士,副主任医师,E-mail: hufan@scu.edu.cn。^*并列第一作者
基金资助:
国家自然科学基金（82071130）

Chinese expert consensus on topical use of timolol maleate gel for the treatment of infantile hemangioma

Zheng Jiawei¹, Wang Xukai², Liu Xuejian³, Jiang Chenghong⁴, Qin Zhongping⁵, Fan Xindong⁶, Li Kai⁷, Yang Yaowu⁸, Huo Ran⁹, Liu Shaohua¹⁰, Zhao Jihong¹¹, Wang Xiaoyong¹², Zhou Dekai¹³, Lei Shaorong¹⁴, Ji Yi¹⁵, Shen Gang¹⁶, Li Haibo¹⁷, Hu Fan¹⁸, Wu Haiwei¹⁹, Dong Changxian²⁰, Wang Qizhang²¹, Wang Huaijie²², Guo Xiaonan²³, Gao Yang²⁴, Gao Xibo²⁵, Guo Lei²⁶

1. Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
2. Department of Oral and Maxillofacial Surgery, School of Stomatology, China Medical University. Shenyang 110001, Liaoning Province;
3. Department of Thyroid and Breast Gland & Hemangioma Surgery, The First Rehabilitation Hospital of Shandong. Linyi 276034, Shandong Province;;
4. Department of Plastic and Reconstructive Surgery, Fujian Medical University, Union Hospital. Fuzhou 350001, Fujian Province;
5. Special Department of Hemangioma, Tumor Hospital of Linyi City. Linyi 276001, Shandong Province;
6. Department of Intervention Therapy, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. Shanghai 200011;
7. Department of Pediatric Surgery, Children's Hospital of Fudan University. Shanghai 201102;
8. Department of Head and Neck Tumor Surgery, School of Stomatology, Air Force Military Medical University. Xi'an 710032, Shaanxi Province;
9. Department of Aesthetic Plastic and Burn Surgery, Shandong Provincial Hospital, Shandong University. Jinan 250021, Shandong Province;
10. Department of Oral and Maxillofacial Surgery, Qilu Hospital, Shandong University. Jinan 250012,Shandong Province;
11. Department of Oral Surgery, School of Stomatology, Wuhan University. Wuhan 430079, Hubei Province;
12. Department of Infantile Hemangioma, Shanghai Cao'an Hospital. Shanghai 201804;
13. Department of Infantile Hemangioma, Gastrointestinal and Neonatal Surgery, Children's Hospital of Chongqing Medical University. Chongqing 400015;
14. Department of Plastic and Esthetic Surgery, Xiangya Hospital Central South University. Changsha 410028, Hunan Province;
15. Department of Pediatric Surgery, and Rare Diseases Center, West China Hospital, Sichuan University. Chengdu 610041, Sichuan Province;
16. Vascular Anomalies and Vascular Interventional Center, Capital Center For Children’s Health, Capital Medical University. Beijing 100020;;
17. Department of Interventional Radiology and Vascular Anomalies, Guangzhou Woman and Children's Medical Center. Guangzhou 510623, Guangdong Province;
18. Department of Pediatric Cardiology, West China Second University Hospital, Sichuan University. Chengdu 610041, Sichuan Province;
19. Department of Stomatology, Shandong Provincial Hospital Affiliated to Shandong First Medical University. Jinan 250021, Shandong Province;
20. Hemangioma and Vascular Malformations Center, Henan Provincial People's Hospital. Zhengzhou 450003, Henan Province;
21. Oral and Maxillofacial Surgery Outpatient Clinic, West China Hospital of Stomatology, Sichuan University. Chengdu 610041, Sichuan Province;
22. Department of Pediatric Surgery & Vascular Anomalies, Xi’an International Medical Center Hospital. Xi’an 710100, Shaanxi Province;;
23. Department of Hemangioma and Vascular Malformation Surgery, The First Affiliated Hospital of Zhengzhou University. Zhengzhou 450052, Henan Province;
24. Department of Hemangioma and Interventional Radiology, Hebei Children's Hospital. Shijiazhuang 050031, Hebei Province;
25. Department of Dermatology, Tianjin Children's Hospital. Tianjin 300202;
26. Department of Vascular Anomalies and Interventional Radiology, Children's Hospital Affiliated to Shandong University（Jinan Children's Hospital）. Jinan 250022, Shandong Province, China

Received:2026-04-16 Revised:2026-05-10 Online:2026-05-20 Published:2026-06-04

摘要/Abstract

摘要： 婴幼儿血管瘤是儿童最常见的良性肿瘤,头面部高发,临床上分为浅表型、深部型与混合型。2025年我国获批上市全球首款治疗婴幼儿血管瘤的外用0.5%马来酸噻吗洛尔凝胶,结束该领域无专用外用药的历史。该药物为非选择性 β受体阻滞剂,通过血管收缩、抗血管生成、诱导内皮细胞凋亡三重机制,促进血管瘤由增殖期向消退期转化。凝胶剂型可延长病灶滞留时间、降低全身吸收与非靶向弥散风险,适合各部位皮肤血管瘤的治疗。基于马来酸噻吗洛尔凝胶逐步推广应用的临床实际,经国内多名来自不同专业、长期从事婴幼儿血管瘤诊治工作的知名专家共同讨论,制订了本专家共识,以供临床参考。

关键词: 婴幼儿血管瘤, 马来酸噻吗洛尔凝胶, 专家共识

Abstract: Infantile hemangioma is the most common benign tumor in children, with a high incidence in the head and face. Clinically, it is classified into superficial, deep, and mixed types. In 2025, China approved the world’s first topical 0.5% timolol maleate gel for the treatment of infantile hemangioma, ending the history of no dedicated topical medication in this field. As a non-selective β-blocker, this drug promotes the transition of hemangiomas from the proliferative phase to the involuting phase through three mechanisms: vasoconstriction, anti-angiogenesis, and induction of endothelial cell apoptosis. The gel formulation prolongs drug retention at the lesion site, reduces systemic absorption and non-target diffusion risks, and is suitable for the treatment of cutaneous hemangiomas at all body sites. Based on the clinical practice of the gradual popularization and application of timolol maleate gel, this expert consensus was developed through joint discussion by many well-known Chinese experts from different specialties engaged in the diagnosis and treatment of infantile hemangioma, for clinical reference.

Key words: Infantile hemangioma, Timolol maleate gel, Expert consensus

中图分类号:

R739.8

郑家伟, 王绪凯, 刘学键, 江成鸿, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 雷少榕, 吉毅, 申刚, 李海波, 胡梵, 吴海威, 董长宪, 王杞章, 王怀杰, 郭晓楠, 高杨, 高西波, 郭磊. 外用马来酸噻吗洛尔凝胶治疗婴幼儿血管瘤中国专家共识[J]. 中国口腔颌面外科杂志, 2026, 24(3): 211-217.

Zheng Jiawei, Wang Xukai, Liu Xuejian, Jiang Chenghong, Qin Zhongping, Fan Xindong, Li Kai, Yang Yaowu, Huo Ran, Liu Shaohua, Zhao Jihong, Wang Xiaoyong, Zhou Dekai, Lei Shaorong, Ji Yi, Shen Gang, Li Haibo, Hu Fan, Wu Haiwei, Dong Changxian, Wang Qizhang, Wang Huaijie, Guo Xiaonan, Gao Yang, Gao Xibo, Guo Lei. Chinese expert consensus on topical use of timolol maleate gel for the treatment of infantile hemangioma[J]. China J Oral Maxillofac Surg, 2026, 24(3): 211-217.

参考文献

[1] Kilcline C, Frieden IJ.Infantile hemangiomas: how common are they? a systematic review of the medical literature[J]. Pediatr Dermatol, 2008, 25(2):168-173.
[2] Waner M, Suen JY.A classification of congenital vascular lesions[C]//Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck[M]. New York: Wiley-Liss, 1999:1-12.
[3] Guo S, Ni N.Topical treatment for capillary hemangioma of the eyelid using β-blocker solution[J]. Arch Ophthalmol, 2010, 128(2): 255-256.
[4] Ni N, Langer P, Wagner R, et al.Topical timolol for periocular hemangioma: report of further study[J]. Arch Ophthalmol, 2011, 129(3):377-379.
[5] Chambers CB, Katowitz WR, Katowitz JA, et al.A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas[J]. Ophthal Plast Reconstr Surg, 2012, 28(2):103-106.
[6] Yu L, Li S, Su B, et al.Treatment of superficial infantile hemangiomas with timolol: evaluation of short-term efficacy and safety in infants[J]. Exp Ther Med, 2013, 6(2):388-390.
[7] Chen ZG, Zheng JW, Yuan ML, et al.A novel topical nano-propranolol for treatment of infantile hemangiomas[J]. Nanomedicine, 2015, 11(5):1109-1115.
[8] 郑家伟, 王绪凯, 江成鸿, 等.外用马来酸噻吗洛尔治疗婴幼儿血管瘤中国专家共识[J].上海口腔医学, 2016, 25(6): 744-747.
Zheng JW, Wang XK, Jiang CH, et al.Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas[J]. Shanghai Journal of Stomatology, 2016, 25(6): 744-747.
[9] Choo W.Simple preparation of timolol 0.5% gel from eye drop solution for superficial infantile hemangiomas[J]. Int J Pharm Compd, 2017, 21(4):282-289.
[10] Rozier A, Mazuel C, Grove J, Plazonnet B.Gelrite: a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. effect on bioavailability of timolol[J]. Int J Pharm, 1989, 57(2):163-168.
[11] Bellale SS, Vansika, Bavage AS, et al.Comparison of dosage forms of common topical drugs[J]. J Emerg Tech Innov Res, 2025, 12(1):d388-d340.
[12] Nieminen T, Lehtimäki T, Mäenpää J, et al.Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects[J]. Scand J Clin Lab Invest, 2007,67(2):237-245.
[13] Höger PH, Hamm H.Infantile hämangiome: manifestationsformen, therapie, differenzialdiagnosen[J]. Dermatologie (Heidelb), 2023, 74(5):331-339.
[14] Kum JJ, Khan ZA.Mechanisms of propranolol action in infantile hemangioma[J]. Dermatoendocrinol, 2014, 6(1):e979699.
[15] Xia M, Ding K, Ji Y, et al.The timing and safety of topical timolol treatment for superficial infantile hemangioma: a retrospective cohort study[J].Eur J Pediatr, 2025, 184(2):151.
[16] Sebaratnam DF, Rodríguez Bandera AL, Wong LF, et al.Infantile hemangioma. part 2: management[J].J Am Acad Dermatol, 2021, 85(6):1395-1404.
[17] Holm A, Mulliken JB, Bischoff J.Infantile hemangioma: the common and enigmatic vascular tumor[J].J Clin Invest, 2024, 134(8):e172836.
[18] Itinteang T, Brasch HD, Tan ST, et al.Expression of components of the renin-angiotensin system in proliferating infantile haemangioma may account for the propranolol-induced accelerated involution[J].J Plast Reconstr Aesthet Surg, 2011, 64(6):759-765.
[19] Dahan E, Abou Jaoude L.Infantile hemangiomas: a review of current treatment options[J].Pediatr Ann, 2023, 52(5):e192-e197.
[20] Kowalska M, Debek W, Matuszczak E.Infantile hemangiomas: an update on pathogenesis and treatment[J]. J Clin Med, 2021, 10(20):4631.
[21] Painter SL, Hildebrand GD.Review of topical beta blockers as treatment for infantile hemangiomas[J]. Surv Ophthalmol, 2016, 61(1):51-58.
[22] Khan M, Boyce A, Prieto-Merino D, et al.The role of topical timolol in the treatment of infantile hemangiomas: a systematic review and meta-analysis[J]. Acta Derm Venereol, 2017, 97(10):1167-1171.
[23] Singh S, Srivastava NK, Upadhyaya A, et al.Efficacy of 0.5% timolol maleate versus 0.05% clobetasol propionate in treating superficial infantile hemangioma: a pilot randomized controlled trial[J]. J Indian Assoc Pediatr Surg, 2025, 30(3):308-316.
[24] Qiao J, Lin J, Zhang D, et al.Efficacy of combined topical timolol and oral propranolol for treating infantile hemangioma: a meta-analysis of randomized controlled trials[J].Front Pharmacol, 2020, 11:554847.
[25] Hasbani DJ, Hamie L.Infantile hemangiomas[J]. Dermatol Clin, 2022, 40(4):383-392.
[26] Muñoz-Garza FZ, Ríos M, Roé-Crespo E, et al.Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage: a randomized clinical trial[J]. JAMA Dermatol, 2021, 157(5):583-587.
[27] 王长凤, 孙佳丽, 吴长华, 等. 595 nm脉冲染料激光联合噻吗洛尔滴眼液治疗浅表性婴幼儿血管瘤的疗效观察[J].临床小儿外科杂志, 2019, 18(11):953-958.
Wang CF, Sun JL, Wu CH, et al.Curative efficacy of timolol plus 595 nm pulsed dye laser for superficial infantile hemangioma[J]. Journal of Clinical Pediatric Surgery, 2019, 18(11):953-958.
[28] Achauer BM, Chang CJ, Vander Kam VM.Management of hemangioma of infancy: review of 245 patients[J]. Plast Reconstr Surg, 1997, 99(5):1301-1308.
[29] Yang L, Chen F, Li K, et al.A retrospective study on the treatment of superficial infantile hemangiomas of the head and neck using topical compresses with 0.5% timolol maleate eye drops[J]. Front Pediatr, 2025, 13:1734987.
[30] Tollefson MM, Frieden IJ.Early growth of infantile hemangiomas: what parents' photographs tell us[J]. Pediatrics, 2012, 130(2):e314-320.
[31] Frommelt P, Juern A, Siegel D, et al.Adverse events in young and preterm infants receiving topical timolol for infantile hemangioma[J].Pediatr Dermatol, 2016, 33(4):405-414.
[32] Wang Z, Denys I, Chen F, et al.Complete atrioventricular block due to timolol eye drops: a case report and literature review[J].BMC Pharmacol Toxicol,2019,20(1):73.
[33] Weibel L, Barysch MJ, Scheer HS, et al.Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption[J].Pediatr Dermatol, 2016, 33(2):184-190.
[34] 日本马来酸噻吗洛尔滴眼液综述资料[OL].(https://www.drugfuture.com/pmda/interview/300237_1319702Q1107_5_07).
Review data of timolol maleate eye drops in Japan[OL].(https://www.drugfuture.com/pmda/interview/300237_1319702Q1107_5_ 07).
[35] Yoon DJ, Kaur R, Gallegos A, et al.Repurposing ophthalmologic timolol for dermatologic use: caveats and historical review of adverse events[J]. Am J Clin Dermatol, 2021, 22(1):89-99.
[36] Drolet BA, Boakye-Agyeman F, Harper B, et al.Systemic timolol exposure following topical application to infantile hemangiomas[J].J Am Acad Dermatol, 2020, 82(3):733-736.
[37] Werpachowski N, Susla L, Lal K.Complications of topical timolol in the management of infantile hemangiomas: a systematic review[J]. J Clin Aesthet Dermatol, 2025, 18(11):48-57.
[38] Ovadia SA, Landy DC, Cohen ER, et al.Local administration of β-blockers for infantile hemangiomas: a systematic review and meta-analysis[J]. Ann Plast Surg, 2015, 74(2):256-262.
[39] Danarti R, Ariwibowo L, Radiono S, et al.Topical timolol maleate 0.5% for infantile hemangioma: its effectiveness compared to ultrapotent topical corticosteroids-a single-center experience of 278 cases[J]. Dermatology, 2016, 232(5):566-571.
[40] Wu HW, Liu C, Wang X, et al.Topical application of 0.5% timolol maleate hydrogel for the treatment of superficial infantile hemangioma[J].Front Oncol, 2017, 27(7):137.

相关文章 15

[1]	黄秋雨, 王帅, 何悦, 郑家伟, 彭歆, 刘冰, 李一, 王安训, 刘习强, 陈传俊, 毕小琴, 杨悦, 吴红梅, 叶艳彬, 肖炜, 陈芸梅, 赵芳, 李燕娥, 周陶, 何杏芳, 王澄, 叶菁菁, 王晓玲, 陈超刚, 侯劲松. 口腔颌面部恶性肿瘤颈淋巴清扫术后乳糜漏临床营养管理专家共识[J]. 中国口腔颌面外科杂志, 2025, 23(5): 425-433.
[2]	何悦, 祝奉硕, 马春跃, 贺捷, 王延安, 李劲松, 刘冰, 蒋灿华, 侯劲松, 彭歆, 何培杰, 张东升, 王军, 刘习强, 杨宏宇, 陈超刚, 吴逸群, 姚原, 苏立新, 刘峰, 马玉波, 朱凌, 温红梅, 黄秋雨. 晚期或复发性口腔（口咽）癌的救治性外科治疗中国专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(6): 521-528.
[3]	邰茂众, 秦中平, 郑家伟, 李克雷, 刘学键, 李凯, 袁斯明, 范新东, 周德凯, 董长宪, 吉毅, 顾松, 霍然, 杨耀武, 王绪凯. 局限性血管内凝血诊断与治疗中国专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(4): 313-321.
[4]	王延安, 秦中平, 郑家伟, 李春洁, 刘少华, 杨耀武, 陈刚, 陈伟良, 刘学键, 杜仲, 张雷, 王业飞, 王德明, 苏立新, 谢峰, 董长宪, 郭磊, 李凯, 顾松, 何悦, 张志愿. 头颈部血管瘤及脉管畸形手术治疗专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(2): 105-117.
[5]	任振虎，陈铭韬，吴汉江，张胜，方坤，谢尚，刘宇，胡传宇，刘冰，李春洁，朱桂全，王成，高洋，张晓晨，石剑波，张永红，崔明哲，季彤，任国欣，王延安，陈伟良，张陈平，何悦，张志愿. 头颈肿瘤围术期静脉血栓栓塞症防治中国专家共识[J]. 中国口腔颌面外科杂志, 2024, 22(1): 1-9.
[6]	何悦, 陈珩, 安金刚, 郭玉兴, 潘剑, 田磊, 刘冰, 侯劲松, 李劲松, 蒋灿华, 李萌宇, 田臻, 许洁, 朱凌, 孙长伏, 郅克谦, 瞿晴, 宗春琳, 孙晶晶, 张志愿. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21(4): 313-325.
[7]	李晓, 范新东, 郑家伟. 脉管异常的ISSVA分类概要及分子生物学研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(3): 286-290.
[8]	郑家伟, 王绪凯, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 刘学键. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识（2022版）[J]. 中国口腔颌面外科杂志, 2022, 20(4): 313-319.
[9]	刘冰, 何悦, 彭歆, 孙长伏, 韩正学, 吴煜农, 彭利伟, 赵熠, 陶谦, 韩新光, 李劲松, 苏彤, 李波, 张雷, 胡砚平, 陈传俊, 李一, 李铁军, 赵怡芳. 牙源性角化囊肿诊疗中国专家共识[J]. 中国口腔颌面外科杂志, 2022, 20(3): 209-218.
[10]	王育新, 王志勇, 王永功, 王慧明, 王丽珍, 田皞, 叶金海, 付坤, 阮敏, 孙长伏, 孙国文, 刘法昱, 许碧云, 后军, 刘冰, 刘亮, 陈永锋, 陈占伟, 肖灿, 李思毅, 李志勇, 李勇, 李楠, 张陈平, 张东升, 张胜, 张凯, 杨溪, 何巍, 苏彤, 季彤, 林李嵩, 罗瑞华, 赵志立, 胡勤刚, 唐瞻贵, 徐蔚嘉, 黄志权, 黄晓峰, 梁玉洁, 韩正学, 韩伟, 蒋灿华, 喻建军, 蔡志刚, 廖贵清, 廖圣恺, 蔡惠明, 魏建华. 吲哚菁绿荧光成像技术在口腔鳞癌治疗中的应用：中国专家共识[J]. 中国口腔颌面外科杂志, 2022, 20(1): 1-6.
[11]	郑家伟, 赵泽亮, 陈启铭. 婴幼儿血管瘤循证治疗现状[J]. 中国口腔颌面外科杂志, 2022, 20(1): 7-14.
[12]	郭伟, 任国欣, 孙沫逸, 孔蕴毅, 王丽珍, 步荣发, 冉炜, 唐瞻贵, 李龙江, 孟箭, 孙志军, 尚伟, 吕炯, 武和明, 张陈平, 何悦, 马旭辉, 宋浩, 鞠侯雨, 郑家伟, 龚忠诚, 杨凯, 张杰, 吴云腾. 中国人口腔黏膜黑色素瘤临床诊治专家共识[J]. 中国口腔颌面外科杂志, 2021, 19(6): 481-488.
[13]	陈传俊, 陈伟良, 孙长伏, 何悦, 蒋灿华, 彭歆, 尚政军, 韩正学, 李劲松, 侯劲松, 林李嵩, 韩新光, 魏建华, 王志勇, 吴煜农, 郑家伟, 李龙江, 王慧明, 李祖兵, 郭传瑸, 杨驰, 石冰, 张志愿. 颏下岛状瓣修复口腔颌面部缺损专家共识[J]. 中国口腔颌面外科杂志, 2021, 19(5): 385-391.
[14]	王杞章, 郑家伟. 口服普萘洛尔治疗婴幼儿增殖期血管瘤:英国儿科皮肤病学会共识及临床指南[J]. 中国口腔颌面外科杂志, 2020, 18(6): 548-552.
[15]	何悦, 蒋灿华, 侯劲松, 王慧明, 彭歆, 刘冰, 李劲松, 郑磊, 徐中飞, 吴煜农, 胡镜宙, 秦兴军, 艾松涛, 周辉红, 李春洁, 张世周, 王军, 李晓光, 刘忠龙, 祝奉硕. 穿支皮瓣修复口腔颌面-头颈部缺损专家共识[J]. 中国口腔颌面外科杂志, 2020, 18(5): 385-389.

外用马来酸噻吗洛尔凝胶治疗婴幼儿血管瘤中国专家共识

Chinese expert consensus on topical use of timolol maleate gel for the treatment of infantile hemangioma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价